As specialty therapies move toward long-term maintenance use and as treatment times grow longer, government and commercial payers are scrutinising the economic value of new treatments more
In an effort to control healthcare costs, provide healthcare to the uninsured and underinsured, and improve health outcomes, there has been growing interest among politicians and the public
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
